{"analyses":[{"groupIds":["OG000","OG001","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"= 0.011","statisticalMethod":"ANOVA"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.2","value":"0.53"},{"groupId":"OG001","spread":"1.0","value":"5.2"},{"groupId":"OG002","spread":"2.6","value":"-0.74"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"14"}],"units":"Participants"}],"description":"Measured at baseline and after one year by QCT.","dispersionType":"Standard Error","groups":[{"description":"15 subjects were treated with combined 60mg denosumab every six months, 30 mg cinacalcet daily and 50 micrograms vitamin-D3 daily.","id":"OG000","title":"Combined Treatment."},{"description":"16 subjects received 60 mg denosumab every six months, placebo and 50 micrograms vitamin-D daily.","id":"OG001","title":"Denosumab Monotherapy"},{"description":"15 subjects will receive a saline injection every six months(blinded), placebo-tablets and 50 micrograms vitamin-D daily.","id":"OG002","title":"Placebo"}],"paramType":"MEAN","populationDescription":"One participant from the combined treatment-group was not included in the analysis due to withdrawal before the final scan. One participant from the denosumab group experienced a wrist fracture prior to the final scan and was excluded. 5 patients did not provide data for the analysis due to errors in the technique of the obtained images.","reportingStatus":"POSTED","timeFrame":"Baseline, one year","title":"Percentage Change in Volumetric BMD for the Distal Forearm.","type":"SECONDARY","unitOfMeasure":"% change"}